Catalog No.
Product Name
Application
Product Information
Citations
-
JNK Inhibitor
Salicortin is a phenolic glycoside that functions as a JNK inhibitor. It effectively inhibits osteoclast differentiation and bone resorption by down-regulating the JNK and NF-κB/NFATc1 signaling pathways. Salicortin exhibits a range of biological activities, including anti-amnesic, anti-adipogenic, and immune-modulatory effects, making it a valuable tool for research in bone metabolism, neurobiology, and immunology. -
NF-κB Inhibitor
Esculentoside H (EsH) is a saponin with inhibitory effects on the NF-κB signaling pathway. It exhibits notable anti-tumor activity, primarily through the modulation of TNF release. EsH has been shown to suppress colon cancer cell migration by inhibiting JNK1/2 and reducing the expression of matrix metalloproteinases-9 (MMP-9), making it a valuable tool for research in cancer biology and therapeutic interventions. -
NF-κB/AP-1 Inhibitor
IQ-1S is an inhibitor of NF-κB and activating protein 1 (AP-1), exhibiting an IC50 of 1.8 μM. It demonstrates significant binding affinity for all three JNK isoforms, with Kd values of 87 nM for JNK3, 360 nM for JNK2, and 390 nM for JNK1. IQ-1S is valuable for researchers investigating the role of JNK signaling pathways and their implications in inflammation and cancer. -
JNK2 Inhibitor
JNK2-IN-1 is a selective inhibitor of JNK2, displaying a dissociation constant (Kd) of 79.2 μM. This compound exhibits anti-inflammatory properties by reducing the secretion of pro-inflammatory cytokines TNF-α and IL-6 through the inhibition of the NF-κB/MAPK signaling pathway. JNK2-IN-1 has demonstrated therapeutic potential in alleviating symptoms associated with LPS-induced acute lung injury (ALI) and sepsis, making it valuable for research in inflammation and related diseases. -
Rare Sugar
D-Psicose is a rare sugar that exhibits its biological activity primarily through the inhibition of p38 MAPK phosphorylation and MCP-1 expression. It effectively targets the AGEs/RAGE/NF-κB signaling pathway, offering protective effects on pancreatic β-islets. Additionally, D-psicose has been shown to improve hyperglycemia and mitigate high-fat diet-induced non-alcoholic fatty liver disease, making it a valuable reagent for research in metabolic disorders and diabetes. -
NF-κB p65 Inhibitor, p38 MAPK Inhibitor
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK, playing a significant role in modulating inflammatory pathways. This compound forms membrane pores and interacts with the human insulin B chain, inhibiting insulin aggregation and contributing to cytotoxic effects through α-type amyloid-like fibril formation. PSMα3 is valuable for research on spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and infections caused by Staphylococcus aureus. -
NF-κB/MAPK Inhibitor
NF-κB/MAPK-IN-1 is a potent inhibitor of the NF-κB and MAPK signaling pathways, exhibiting significant biological activity in the modulation of inflammatory responses. It effectively reduces nitric oxide (NO) production with an IC50 of 6.96 µM and inhibits the activation of iNOS, COX-2, ERK, and p38 signaling pathways induced by LPS. This compound is valuable for research applications focused on inflammatory diseases, including rheumatoid arthritis. -
NF-κB/MMP9/MAPK Inhibitor
Isoliquiritin apioside is an inhibitor of NF-κB, MMP9, and MAPK signaling pathways. It has been shown to significantly reduce PMA-induced MMP9 activity and suppress the activation of MAPK and NF-κB. This compound is relevant for research applications focused on cancer biology, particularly in the investigation of mechanisms underlying cell invasiveness and angiogenesis in both cancer and endothelial cells. -
PDE4 Inhibitor
Glaucine, a selective phosphodiesterase 4 (PDE4) inhibitor, is an alkaloid sourced from Glaucium flavum. It demonstrates significant biological activities such as bronchodilation, anti-inflammatory effects, and anticancer properties. With a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes, Glaucine promotes relaxation of isolated human bronchi through calcium channel antagonism. Furthermore, it inhibits NF-κB activation, which downregulates MMP-9 expression, thereby impairing the migration and invasion of breast cancer cells. Glaucine is relevant for research applications in asthma and breast cancer. -
PDE4 Inhibitor
LT-104A is a selective phosphodiesterase 4 (PDE4) inhibitor that effectively elevates intracellular cyclic AMP (cAMP) levels, exhibiting an EC50 of 1.9 μM and inhibiting PDE4D3 activity with an IC50 of 9.3 μM. By activating the cAMP-PKA-CREB anti-inflammatory signaling pathway, LT-104A suppresses expression of NF-κB-related genes such as Il1b and Nos2. This compound is valuable for research focused on inflammation-related diseases and therapeutic interventions aimed at modulating inflammatory responses. -
Stable Isotope
Vinpocetine-d5 is a deuterium-labeled derivative of Vinpocetine, which primarily inhibits voltage-gated sodium channels. It serves as a phosphodiesterase (PDE) inhibitor, effectively disrupting NF-κB-dependent inflammatory responses by directly targeting the IκB kinase complex (IKK), with an IC50 of 17.17 μM in a cell-free system. This compound is valuable in research related to cerebrovascular disorders and inflammation, enabling the tracking and analysis of Vinpocetine's biological effects in various applications. -
isoquinoline alkaloid
Antidesmone is an isoquinoline alkaloid derived from Antidesma membranaceum, known for its ability to inhibit the activities of MAPK and NF-κB pathways. This compound demonstrates significant potential in preventing acute lung injury in vivo, making it valuable for research into inflammatory diseases and related therapeutic interventions. Its mechanistic insights can facilitate studies aimed at understanding the pathophysiology of lung injuries and exploring novel treatment strategies. -
Neuroprotective Agent
Deoxysappanone B is a homoisoflavone compound that exhibits neuroprotective properties by targeting the IκB kinase (IKK)-NF-κB and p38/ERK MAPK signaling pathways. This compound demonstrates significant anti-neuroinflammatory activity by inhibiting the production of neuroinflammatory mediators. Deoxysappanone B is a valuable tool for research concerning neuritis and inflammation-related neurological disorders, offering insights into potential therapeutic strategies for neurodegenerative diseases. -
PI3K/Akt Inhibitor, MAPK Inhibitor, NF-κB Inhibitor, Nrf2/ARE Activator
JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms. -
p38 MAPK Inhibitor
Ganoderterpene A is a potent inhibitor of p38 MAPK, demonstrating significant anti-inflammatory and anti-apoptotic activity. It effectively attenuates LPS-induced inflammation and apoptosis by suppressing the MAPK and TLR-4/NF-κB signaling pathways in BV-2 cells. This compound is valuable for research applications focused on neuroinflammation and cellular stress responses. -
MAPK/NF-κB Inhibitor
Masticadienonic acid is a selective inhibitor of the MAPK pathway (including p38, ERK, and JNK) and the NF-κB signaling cascade, while also acting as an agonist of the Nrf2 pathway. This compound effectively reduces the release of proinflammatory cytokines such as TNFα, IL-1β, and IL-6, and it restores the expression of intestinal tight junction proteins, including ZO-1 and occludin. Its regulatory effects on intestinal flora and inflammation make it suitable for research applications in inflammatory bowel disease and leishmaniasis. -
Potassium-competitive Acid Blocker
KFP-H008 is an orally active potassium-competitive acid blocker that targets H+-K+-ATPase to inhibit gastric acid secretion. This compound has shown efficacy in reducing ethanol-induced gastric ulcer index and decreasing malonaldehyde levels, along with the expression of pro-inflammatory cytokines in vivo. KFP-H008 also downregulates p-p38 MAPK and p65 NF-κB expression, demonstrating its potential in mitigating gastric inflammation. This reagent is valuable for research into acid-related diseases, including gastric ulcers and gastric epithelial cell damage. -
PAR2 Antagonist
K-14585 is a peptide that acts as a competitive antagonist of protease-activated receptor 2 (PAR2). It effectively inhibits PAR2-mediated interleukin-8 (IL-8) production, as well as phosphorylation of NF-κB and p38 MAPK signaling pathways. Additionally, K-14585 significantly reduces calcium mobilization induced by the PAR2 agonist SLIGKV in primary human keratinocytes, making it a valuable tool for studying PAR2-related biological processes and inflammatory responses. -
NF-κB/MAPK Inhibitor
Isonardosinone is a nardosinone-type sesquiterpene that primarily targets the NF-κB and MAPK signaling pathways. It effectively inhibits the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide-induced BV2 microglial cells, demonstrating significant anti-inflammatory activity. This compound is valuable for research applications focused on inflammation and neurodegenerative diseases. -
p38 MAPK Inhibitor
Anti-inflammatory agent 7 is a selective p38 MAPK inhibitor that modulates the NF-κB/MAPK signaling pathway to inhibit proinflammatory cytokine production. This reagent demonstrates significant anti-inflammatory activity in LPS-treated RAW 264.7 cells and in in vivo models, making it a valuable tool for studying inflammatory responses and developing therapeutic strategies for related diseases. -
Anti-Osteoporosis Compound
Anti-osteoporosis agent-11, a selective anti-osteoporosis compound, targets osteoclasts to impede their differentiation. This compound exhibits potent inhibitory activity with an IC50 value of 0.36 μM, effectively suppressing osteoclast formation, bone resorption, and the expression of osteoclast-specific genes. Its mechanism involves the blockade of RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways, making it a valuable tool for research in osteoporosis treatment and bone metabolism studies. -
Alkaloid
β-Carboline-1-carboxylic acid is a β-carboline alkaloid that acts as an inhibitor of phosphodiesterase and indoleamine 2,3-dioxygenase, demonstrating an IC50 of 96 µM for cAMP phosphodiesterase. It exhibits significant biological activities including anti-inflammatory, antifibrotic, antitumor, and antibacterial properties, with cytotoxic effects on tumor cells. Furthermore, this compound inhibits inflammation via the NF-κB/p65 pathway and reverses epithelial-mesenchymal transition (EMT). It also shows potent antibacterial effects against Staphylococcus aureus and Escherichia coli, with IC50 values of 47.70 μg/mL and 19.17 μg/mL, respectively. -
Anti-neuroinflammatory Agent
SB26019 is a potent anti-neuroinflammatory agent that primarily targets NF-κB activation. It functions by promoting the formation of monomeric α-tubulin, which in turn inhibits the translocation of the p65 subunit of NF-κB. This mechanism underscores its potential application in neuroscience research, particularly in studies related to neuroinflammation and associated disorders. -
MyD88 Inhibitor
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways, targeting the Toll/IL-1 receptor (TIR) domain of MyD88 to disrupt its homodimeric formation. This compound effectively inhibits NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity, demonstrating notable anti-inflammatory effects with IC50 values of 2.7 μM for IFN-γ, 2.9 μM for IL-1β, 2.66 μM for IL-6, and 2.66 μM for TNF-α. T6167923 serves as a valuable tool in studying the role of MyD88 signaling in inflammatory responses and therapeutic interventions. -
Myd88 Inhibitor
MyD88-IN-1 is a potent inhibitor of MyD88, targeting the interaction between TLR4 and MyD88. By suppressing the NF-κB signaling pathway, MyD88-IN-1 demonstrates significant biological activity relevant to cancer and inflammatory research. This compound serves as a valuable tool for elucidating the role of MyD88 in various disease processes and therapeutic interventions. -
Influenza Virus Inhibitor
Amizon is an orally effective antiviral agent targeting the influenza virus. It inhibits viral replication and restricts RNA synthesis, while simultaneously reducing the mRNA expression of pro-inflammatory mediators such as COX-1, COX-2, NF-κB, TGF-β1, IL-1, and IL-6. Additionally, Amizon enhances the secretion and mRNA expression of the anti-inflammatory cytokine IL-10 and exhibits antioxidant properties, inhibiting the oxidative activity of macrophages. This compound is of interest in research focused on influenza and acute respiratory viral infections. -
Parasite Inhibitor
8-Deoxygartanin, a prenylated xanthone derived from Garcinia mangostana, serves as a selective inhibitor of butyrylcholinesterase (BChE). This compound demonstrates significant antiplasmodial activity, with an IC50 value of 11.8 μM against the W2 strain of Plasmodium falciparum. Additionally, 8-Deoxygartanin inhibits NF-κB (p65) activation, displaying an IC50 of 11.3 μM, making it a valuable reagent for research in parasitic infections and inflammation pathways. -
Stable Isotope
Estragole-d4 is a deuterated form of Estragole, primarily utilized as a stable isotope for labeling studies. As a volatile terpenoid ether, Estragole exhibits significant biological activities, including the induction of apoptosis and the inhibition of LPS-induced reactive oxygen species (ROS) production. It also activates the Nrf-2 pathway and regulates NF-κB signaling, contributing to its anti-inflammatory, antioxidant, and immunomodulatory properties. Estragole has been investigated for its potential effects on neuronal excitability and gastric ulcer amelioration, making it valuable in various research applications. -
Quinazoline alkaloid
Dehydroevodiamine is a key bioactive quinazoline alkaloid derived from Evodiae Fructus, primarily known for its antiarrhythmic properties demonstrated in guinea pig ventricular myocytes. This compound effectively inhibits the expression of lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), and nuclear factor-kappa B (NF-κB) in murine macrophage cells. Its diverse biological activities make it a valuable reagent for research focused on cardiovascular function and inflammatory responses. -
Syk Inhibitor
DBMB is a selective inhibitor of spleen tyrosine kinase (Syk) that effectively attenuates Syk kinase activity. Its mechanism of action involves the suppression of NF-κB signaling, leading to a decrease in the production of key inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB is suitable for investigations focused on inflammatory diseases and elucidating the role of Syk in immune response pathways. -
iNOS Inhibitor
Asperuloside is an iridoid compound derived from Hedyotis diffusa, primarily known for its role as an inducible nitric oxide synthase (iNOS) inhibitor. This compound exhibits notable anti-inflammatory properties by suppressing the NF-κB and MAPK signaling pathways. Asperuloside is valuable in studying inflammatory processes and developing therapeutic strategies for related diseases. -
NF-κB Inhibitor
Neocryptotanshinone is a potent NF-κB inhibitor derived from Salvia miltiorrhiza. This compound effectively suppresses lipopolysaccharide-induced inflammation by targeting and inhibiting the NF-κB and iNOS signaling pathways. It shows promise in research applications focused on inflammatory diseases and provides valuable insights into the mechanisms of immune response modulation. -
iNOS/Nf-Κb Inhibitor
Hymenoxin is a dual inhibitor of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB), exhibiting IC50 values of 42.7 μM and 85.5 μM, respectively. This compound demonstrates the capacity to reduce oxidative stress by 16% at a concentration of 125 μg/mL. Hymenoxin is primarily utilized in research focused on inflammatory responses and related signaling pathways. Its inhibitory effects on key regulators make it valuable for studies investigating the roles of iNOS and NF-κB in various disease models. -
Anti-apoptotic Agent
Bacoside A is an anti-apoptotic triterpenoid saponin derived from Bacopa monnieri, known for its ability to penetrate the blood-brain barrier. It exhibits significant antioxidant, anti-inflammatory, and neuroprotective properties by modulating the activities of ATPases, AChE, CaMK2A, and iNOS. Bacoside A helps maintain ion balance, scavenges reactive oxygen species, and regulates NF-κB and apoptosis-related proteins, thereby protecting nerve cells from stress-induced damage and exerting non-apoptotic cytotoxicity against glioblastoma cells. Its applications extend to research in neurological disorders, including Parkinson's disease and glioblastoma multiforme. -
Anti-Inflammatory Agent
PPM-18 (NSC 73233) is a potent anti-inflammatory agent that inhibits nitric oxide synthase (iNOS) expression by preventing NF-κB from binding to its promoter. This compound has demonstrated the ability to induce autophagy and apoptosis in bladder cancer cells, mediated through reactive oxygen species (ROS) and AMP-activated protein kinase (AMPK) signaling pathways. PPM-18 is valuable for researchers studying inflammation and cancer therapeutics. -
NOS Inhibitor
SDMA (p-hydroxyazobenzene-p′-sulfonate) is a potent endogenous inhibitor of nitric oxide synthase (NOS), making it a valuable tool for studying NOS-related pathways. This compound has been shown to activate NF-κB, leading to increased expression of pro-inflammatory cytokines such as IL-6 and TNF-α. Additionally, SDMA demonstrates stability in serum and plasma, allowing its use as a biomarker for assessing hepatic and renal dysfunction in various research applications. -
iNOS/ICAM-1 Inhibitor
Aloenin aglycone is an inhibitor of iNOS and ICAM-1, derived from aloe exudate. It effectively suppresses TNFα-induced NF-κB transcriptional activity with an IC50 of 18.7 μM. Additionally, at a concentration of 10 μM, it significantly reduces the expression of both inducible nitric oxide synthase (iNOS) and intercellular adhesion molecule 1 (ICAM-1) in HepG2 cells following TNFα stimulation. This compound serves as a valuable tool for investigating inflammatory pathways and potential therapeutic interventions in related conditions. -
Anti-inflammatory Agent
Anti-inflammatory Agent 65 is a Hederagonic acid derivative that exhibits significant anti-inflammatory activity. This compound effectively inhibits the release of nitric oxide (NO) and prevents the nuclear translocation of IRF3 and p65. By disrupting the STING/IRF3/NF-κB signaling pathway, Anti-inflammatory Agent 65 significantly reduces the inflammatory response, making it a valuable tool for studying inflammation-related conditions and potential therapeutic interventions. -
FOXP3 Inhibitor
Peptide P60 is a potent FOXP3 inhibitor that disrupts the nuclear translocation of FOXP3, thereby decreasing its regulatory effects on NF-κB and NFAT signaling pathways. This action inhibits the immunosuppressive capabilities of regulatory T cells, facilitating the proliferation and activation of effector T cells. Experimental studies have shown that Peptide P60 can induce lymphoproliferative autoimmune syndrome in neonatal ICR mice and diminish the population of CD4+CD25+Foxp3+ T cells in the spleen. Additionally, it enhances the efficacy of peptide vaccines and recombinant adenovirus-based vaccines, making it valuable for research in tumor immunology, viral infections, and autoimmune conditions. -
RANKL Inhibitor
RANKL-IN-1 is a selective and orally bioactive inhibitor of Receptor Activator of Nuclear Factor-κB Ligand (RANKL), displaying a KD value of 7.6 μM. This compound effectively inhibits osteoclastogenesis with an IC50 of 0.07 μM and a selectivity index of 82.57. RANKL-IN-1 directly interacts with RANKL, preventing downstream activation of the NF-κB and MAPK signaling pathways. It is a valuable tool for investigating metabolic disorders, particularly osteoporosis. -
STING Inhibitor
STING-IN-4 is a potent STING inhibitor that effectively reduces the expression and activation of STING and nuclear factor-κB (NF-κB) signaling pathways. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for investigating sepsis and related inflammatory conditions. Researchers can utilize STING-IN-4 to explore the therapeutic potential of modulating STING activity in various biological contexts. -
STING PROTAC Degrader
PROTAC STING degrader-3 is a potent STING PROTAC degrader that operates through the ubiquitin-proteasome pathway, exhibiting a DC50 of 0.62 μM. This compound facilitates STING degradation, resulting in the inhibition of STING/TBK1/NF-κB signaling, thereby exerting notable anti-inflammatory effects. Additionally, PROTAC STING degrader-3 demonstrates renal protective properties and serves as a valuable tool for investigating acute kidney injury (AKI). -
Cyclic Guanosine Monophosphate
3'2'-cGAMP is a cyclic guanosine monophosphate-adenosine monophosphate isomer that selectively targets Drosophila STING (dSTING). It activates the dSTING-NF-κB signaling pathway, leading to the upregulation of Sting-regulated genes and establishing a robust antiviral state in vivo. Additionally, 3'2'-cGAMP is resistant to degradation by viral poxins, making it a valuable tool for investigating viral infections and related biological processes. -
NF-κB Inhibitor
Eupenicisirenin C is a potent inhibitor of the NF-κB signaling pathway. This compound effectively suppresses the cGAS-STING pathway, demonstrating significant potential in modulating inflammatory responses. Notably, Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophages, making it a valuable tool for research into bone metabolism and inflammatory diseases. -
TLR7 Agonist
SMU-L11 is a selective TLR7 agonist with an EC50 of 0.024 μM, which engages the MyD88 adapter protein to activate downstream NF-κB and MAPK signaling pathways. This compound significantly enhances immune cell activation in murine models, promoting the proliferation of CD4+ T and CD8+ T cells, leading to direct tumor cell lysis and inhibition of tumor growth. SMU-L11 is a valuable reagent for cancer research and can also be utilized for investigations into immune system-related diseases. -
BACH1 Inhibitor
ASP-8731 is a potent BACH1 inhibitor that enhances NRF2-mediated gene transcription, thereby activating antioxidant and anti-inflammatory pathways. This compound significantly upregulates the expression of key genes such as HMOX1 and FTH1, and increases fetal hemoglobin (HbF) levels, promoting F-cell production in hydroxyurea-unresponsive cells. Additionally, ASP-8731 mitigates inflammatory responses by downregulating VCAM1, ICAM-1, and NF-κB (p65) phosphorylation. Its ability to relieve glutathione depletion and microcirculatory stasis suggests potential applications in the treatment of sickle cell disease and other hematological disorders. -
Stable Isotope
Oxaprozin-d5 is a deuterium-labeled derivative of Oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID) that functions as a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 2.2 μM and 36 μM, respectively, for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2. Additionally, Oxaprozin is known to inhibit the activation of NF-κB. This stable isotope can be utilized in pharmacokinetic studies and metabolic research, enhancing the understanding of Oxaprozin's biological pathways and mechanisms of action. -
Stable Isotope
Guaiacol-d4-1 is a deuterated form of guaiacol that serves as a stable isotope. This phenolic compound is known to inhibit lipopolysaccharide (LPS)-induced cyclooxygenase-2 (COX-2) expression and activation of nuclear factor kappa B (NF-κB), demonstrating significant anti-inflammatory activity. It is widely used in research applications focused on inflammation and signaling pathways in various biological systems. -
COX-2 Inhibitor
COX-2-IN-51 is a selective COX-2 inhibitor exhibiting an IC50 of 70.7 nM. It effectively reduces LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2), as well as the expression of COX-2 and inducible nitric oxide synthase (iNOS), and inhibits the NF-κB signaling pathway. This compound demonstrates anti-inflammatory and analgesic properties in various murine models by targeting the NF-κB cascade, while presenting a lower risk of gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs. -
Active Compound
threo-Guaiacylglycerol β-coniferyl ether is an active compound derived from the 95% ethanol extract of Lepisorus contortus, a member of the Polypodiaceae family. Although its inhibitory activity against key targets such as NF-κB, nitric oxide production, aromatase, quinone reductase 2, and cyclooxygenase (COX-1/-2) is not pronounced, it serves as a valuable research tool for exploring biochemical pathways. Investigators can utilize this compound in studies focusing on plant-derived metabolites and their potential applications in pharmacology and biochemistry.
